Benzinga | May 7, 2021 06:51AM EDT

SVB Leerink Upgrades Epizyme to Outperform, Raises Price Target to $16

SVB Leerink analyst Andrew Berens upgrades Epizyme (NASDAQ:EPZM) from Market Perform to Outperform and raises the price target from $12 to $16.